Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$39.71
-$0.34(-1.94%)
At close: 4:00 PM EST
$39.71
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$7.73 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)363.42K
Market Cap
$1.62B
Enterprise Value$1.26B
Total Cash (Recent Filing)$490.54M
Total Debt (Recent Filing)$11.48M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 07, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding47,792,942
10 Day Avg. Volume396,096
30 Day Avg. Volume363,417
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.74K
Enterprise Value/Ebitda-10.38
Forecast
1Y Price Target
$50.60Price Target Upside27.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
China PartnershipStrategic licensing agreement granting exclusive development and commercialization rights in Greater China provides upfront payments, milestone potential, and tiered royalties that can accelerate regional development and supply non-dilutive funding.
Long-acting FormulationDevelopment of a long-acting injectable formulation of RAP-219 could reduce breakthrough seizures and improve medication adherence, potentially increasing adoption among patients with refractory focal onset epilepsy.
Phase III AdvancementAdvancement of RAP-219 into registrational Phase III trials for focal seizures with planned expansion into primary generalized tonic-clonic seizures increases the therapy's potential addressable market and clarifies the regulatory pathway.
Bears Say
Analyst CredibilityBusiness relationships between the research firm and covered companies could weaken confidence in analyst recommendations and complicate investor interpretation of research signals.
Conflict Of InterestThe covering research firm conducts business with companies it covers, creating potential conflicts of interest that may undermine the perceived objectivity of analyst reports.
Investor ConfidenceDisclosure of commercial ties between the research firm and covered companies could prompt investor skepticism and increase volatility around the stock's valuation.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $7.73 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.62B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Mar 10, 2026. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$0.043.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.62.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,792,942 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went down -2.98%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.60 (27.42% Upside)
$50.60 (27.42% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 270.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.23%
12-Months-Change
Fundamentals
Return on Equity
-28.85%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$50.60
▲(27.42% Upside)
Technical Analysis
Ownership Overview
23.46% Insiders
24.55% Mutual Funds
0.78% Other Institutional Investors
43.43% Public Companies and
Individual Investors